Circle Pharma’s first-in-class orally bioavailable macrocyclic cyclin A/B inhibitors highlighted in poster presentations at American Association for Cancer Research Annual Meeting Epsilon09242023-04-19T20:23:19-07:00April 19, 2023|Press Releases|
Circle Pharma appoints Stephen Kelsey, MB ChB, MD, to its board of directors Epsilon09242022-12-15T09:07:54-08:00December 15, 2022|Press Releases|
Circle Pharma Appoints Paul Park, MBA, as its Chief Business Officer Epsilon09242022-12-13T18:06:03-08:00July 26, 2022|Press Releases|
Circle Pharma announces presentation at the American Association for Cancer Research 2022 Annual Meeting Epsilon09242022-12-13T18:06:55-08:00April 11, 2022|Press Releases|
Circle Pharma appoints Evelyn Wang, PhD as its Vice President, Translational Medicine Epsilon09242022-05-08T22:15:44-07:00July 12, 2021|Press Releases|
Circle Pharma raises $66 Million in Series C Financing Epsilon09242022-05-08T22:16:13-07:00June 16, 2021|Press Releases|
Circle Pharma appoints Constantine Kreatsoulas, PhD as its Vice President, Research Informatics and Computational Chemistry Epsilon09242022-05-08T22:16:42-07:00February 1, 2021|Press Releases|
Circle Pharma Appoints James Aggen, PhD as Its Vice President, Medicinal Chemistry Epsilon09242022-05-08T22:17:25-07:00October 26, 2020|Press Releases|
Circle Pharma Appoints Alan Ashworth, PhD, FRS and Bruce Stillman, PhD, FRS to Its SAB Epsilon09242022-05-08T22:17:56-07:00October 21, 2020|Press Releases|
Circle Pharma Appoints Rajinder Singh, PhD as its Chief Science Officer Epsilon09242022-05-08T22:18:54-07:00July 20, 2020|Press Releases|
